A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 12th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 621 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 29th largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2013, is one of 86 in phase 3, and was the 158th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo.
The trial includes a 13-15 week run-in period prior to randomization, and a 26-week, double-blind, placebo-controlled treatment period followed by a 78-week double-blind, extension period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
Drug: Ertugliflozin 5 mg · Drug: Placebo to Ertugliflozin · Other: Glimepiride · Drug: Placebo to Glimepiride · Biological: Basal Insulin · Drug: Metformin
Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
Drug: Ertugliflozin 15 mg · Other: Glimepiride · Drug: Placebo to Glimepiride · Biological: Basal Insulin · Drug: Metformin
Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
Drug: Placebo to Ertugliflozin · Other: Glimepiride · Biological: Basal Insulin · Drug: Metformin
Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
Also known as: MK-8835
Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
Also known as: MK-8835
Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
Also known as: Amaryl, GLIMPID, GLIMY
Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
Also known as: Insulin glargine, Insulin detemir, NPH insulin, Degludec
Metformin \>=1500 mg/day, orally, once a day
Also known as: Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor, Metfogamma
Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.
Time frame: Up to Week 106
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.
Time frame: Up to Week 104
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 26
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 26
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
Time frame: Up to Week 26
Time to Glycemic Rescue Therapy at Week 26
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
Time frame: Week 26
Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 52
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 52
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 52
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
Time frame: Up to Week 52
Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)
The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)
This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 52
Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 104
Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 104
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 104
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 104
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104
Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
Time frame: Up to Week 104
Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)
The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 104
Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)
This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 104
Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)
This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 104
Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)
Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 26
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 52
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
Time frame: Baseline and Week 104
| Milestone | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Started | 209 | 207 | 205 |
| Completed | 175 | 187 | 180 |
| Not completed | 34 | 20 | 25 |
| Withdrew: Adverse event | 3 | 1 | 3 |
| Withdrew: Death | 3 | 1 | 2 |
| Withdrew: Excluded medication | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 8 | 5 | 6 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Participant moved | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 18 | 10 | 13 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percent A1C | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in A1C at Week 26 (Excluding Rescue Approach) | -0.03 (-0.15 to 0.10) | -0.73 (-0.85 to -0.61) | -0.91 (-1.03 to -0.78) |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) | 77.5 | 70.5 | 75.6 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) | 2.4 | 3.4 | 3.9 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mg/dL | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) | -0.85 (-5.93 to 4.23) | -27.54 (-32.36 to -22.73) | -39.10 (-43.96 to -34.23) |
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Kilograms | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) | -1.33 (-1.74 to -0.92) | -3.01 (-3.40 to -2.62) | -2.93 (-3.33 to -2.53) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) | 15.8 | 35.3 | 40.0 |
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) | -0.70 (-2.46 to 1.06) | -4.38 (-6.01 to -2.75) | -5.20 (-6.87 to -3.54) |
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) | 0.23 (-0.85 to 1.31) | -1.59 (-2.59 to -0.59) | -2.19 (-3.21 to -1.17) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) | 2.9 | 8.7 | 12.2 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26 | 17.7 | 2.9 | 1.5 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
| Days | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Time to Glycemic Rescue Therapy at Week 26 | 105 (15 to 183) | 112 (23 to 151) | 139 (127 to 145) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percent A1C | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in A1C at Week 52 (Excluding Rescue Approach) | -0.68 ± 0.99 | -0.72 ± 0.95 | -0.96 ± 0.88 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mg/dL | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy) | -12.0 ± 40.0 | -22.4 ± 39.3 | -35.2 ± 40.7 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach) | 30.6 | 34.8 | 36.6 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach) | 11.0 | 10.6 | 14.6 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52 | 17.2 (12.37 to 23.04) | 4.3 (2.01 to 8.09) | 1.5 (0.3 to 4.22) |
The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Kilograms | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach) | 0.07 ± 2.85 | -3.23 ± 3.68 | -3.35 ± 3.27 |
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach) | 0.65 ± 13.38 | -2.63 ± 14.40 | -4.28 ± 13.28 |
This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach) | 0.38 ± 8.16 | -1.40 ± 9.60 | -1.19 ± 7.74 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percent A1C | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in A1C at Week 104 (Excluding Rescue Approach) | -0.58 ± 0.93 | -0.60 ± 0.97 | -0.89 ± 0.90 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mg/dL | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach) | -10.9 ± 44.3 | -18.2 ± 43.5 | -28.2 ± 44.9 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach) | 19.1 | 24.6 | 33.7 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of Participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach) | 7.2 | 10.6 | 12.2 |
Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.
| Percentage of participants | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104 | 24.4 (18.74 to 30.8) | 11.1 (7.18 to 16.2) | 10.7 (6.85 to 15.8) |
The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Kilograms | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach) | -0.18 ± 3.38 | -3.77 ± 4.29 | -3.63 ± 3.86 |
This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach) | 0.05 ± 13.76 | -3.61 ± 12.78 | -3.13 ± 14.11 |
This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach) | -0.46 ± 8.77 | -2.36 ± 9.23 | -1.52 ± 8.61 |
Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| ng/mL | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Week 6:Pre-dose | NA ± NA | 14.89 ± 28.11 | 38.38 ± 74.83 |
| Week 12:Pre-dose | NA ± NA | 12.34 ± 26.07 | 29.23 ± 55.63 |
| Week 12:60 mins post-dose | NA ± NA | 74.84 ± 51.58 | 228.13 ± 139.14 |
| Week 18:Pre-dose | 0.01 ± 0.10 | 9.91 ± 21.18 | 24.46 ± 39.97 |
| Week 18:60 mins post-dose | 0.01 ± 0.09 | 74.39 ± 49.77 | 214.96 ± 147.36 |
| Week 30:Pre-dose | 0.15 ± 1.07 | 12.66 ± 25.50 | 30.55 ± 60.33 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percentage change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach) | 0.22 (-0.20 to 0.65) | -0.01 (-0.42 to 0.41) | 0.12 (-0.31 to 0.55) |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach) | -0.40 (-0.89 to 0.09) | -0.10 (-0.57 to 0.38) | 0.30 (-0.19 to 0.79) |
BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach) | -0.63 (-0.92 to -0.34) | -0.55 (-0.83 to -0.27) | -0.36 (-0.65 to -0.07) |
BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach) | 0.06 (-0.35 to 0.47) | -0.15 (-0.55 to 0.24) | -0.13 (-0.53 to 0.28) |
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach) | 10.8 ± 106.6 | 51.9 ± 121.9 | 80.2 ± 149.7 |
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach) | 0.5 ± 11.7 | 0.8 ± 12.1 | 0.5 ± 15.0 |
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach) | -0.98 ± 6.71 | 0.28 ± 7.52 | 0.14 ± 7.53 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach) | -0.10 (-0.60 to 0.40) | -0.28 (-0.77 to 0.20) | 0.07 (-0.43 to 0.57) |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach) | -0.69 (-1.25 to -0.14) | -0.49 (-1.04 to 0.06) | -0.44 (-1.06 to 0.17) |
BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach) | -0.82 (-1.19 to -0.46) | -1.04 (-1.41 to -0.67) | -1.32 (-1.69 to -0.94) |
BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach) | -0.44 (-0.95 to 0.06) | -0.59 (-1.04 to 0.14) | -0.39 (-0.90 to 0.12) |
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach) | 15.54 ± 43.34 | 34.36 ± 52.74 | 41.57 ± 50.69 |
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent Change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach) | 24.50 ± 120.29 | 8.41 ± 30.95 | 19.79 ± 79.57 |
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent Change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach) | 8.11 ± 52.05 | 11.09 ± 41.80 | 2.48 ± 36.57 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach) | 0.09 (-0.47 to 0.66) | -0.19 (-0.72 to 0.35) | -0.13 (-0.68 to 0.42) |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach) | -1.23 (-1.86 to -0.61) | -1.11 (-1.74 to -0.49) | -0.96 (-1.67 to -0.26) |
BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach) | -1.18 (-1.63 to -0.73) | -1.72 (-2.19 to -1.25) | -2.02 (-2.51 to -1.53) |
BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach) | -0.58 (-1.13 to -0.03) | -0.40 (-0.87 to 0.06) | -0.64 (-1.19 to -0.09) |
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach) | 19.29 ± 71.73 | 26.94 ± 58.44 | 32.53 ± 59.29 |
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach) | 19.38 ± 93.02 | 10.11 ± 39.14 | 24.21 ± 83.23 |
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.
| Percent change | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach) | 10.12 ± 60.13 | 8.16 ± 40.97 | 5.46 ± 38.53 |
Collected over Up to 106 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Glimepiride | 3/209 (1.4%) | 22/209 (10.5%) | 103/209 (49.3%) |
| Ertugliflozin 5 mg | 1/207 (0.5%) | 20/207 (9.7%) | 79/207 (38.2%) |
| Ertugliflozin 15 mg | 2/205 (1%) | 20/205 (9.8%) | 100/205 (48.8%) |
| Event | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Peripheral ischaemiaVascular disorders | 0/209 | 0/207 | 2/205 |
| Angina unstableCardiac disorders | 0/209 | 2/207 | 1/205 |
| Atrial fibrillationCardiac disorders | 0/209 | 2/207 | 1/205 |
| Myocardial infarctionCardiac disorders | 1/209 | 2/207 | 1/205 |
| PancreatitisGastrointestinal disorders | 2/209 | 0/207 | 0/205 |
| Cardiac failureCardiac disorders | 0/209 | 0/207 | 1/205 |
| Myocardial ischaemiaCardiac disorders | 0/209 | 0/207 | 1/205 |
| Sinus node dysfunctionCardiac disorders | 0/209 | 0/207 | 1/205 |
| Myocardial bridgingCongenital, familial and genetic disorders | 0/209 | 0/207 | 1/205 |
| PhimosisCongenital, familial and genetic disorders | 0/209 | 0/207 | 1/205 |
| Event | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 43/209 | 14/207 | 18/205 |
| Upper respiratory tract infectionInfections and infestations | 33/209 | 23/207 | 21/205 |
| Viral upper respiratory tract infectionInfections and infestations | 21/209 | 12/207 | 9/205 |
| Back painMusculoskeletal and connective tissue disorders | 10/209 | 9/207 | 20/205 |
| Urinary tract infectionInfections and infestations | 13/209 | 6/207 | 17/205 |
| Weight decreasedInvestigations | 3/209 | 9/207 | 15/205 |
| HeadacheNervous system disorders | 10/209 | 14/207 | 11/205 |
| InfluenzaInfections and infestations | 12/209 | 11/207 | 10/205 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/209 | 7/207 | 11/205 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/209 | 8/207 | 8/205 |
All randomized and treated participants
| Age, Continuous(Years) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Mean | 56.5 ± 8.7 | 56.6 ± 8.2 | 56.9 ± 9.4 | 56.6 ± 8.8 |
| Sex: Female, Male(Participants) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Female | 111 | 110 | 112 | 333 |
| Male | 98 | 97 | 93 | 288 |
| Race (NIH/OMB)(Participants) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 31 | 34 | 35 | 100 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 19 | 22 | 23 | 64 |
| White | 144 | 134 | 133 | 411 |
| More than one race | 15 | 17 | 14 | 46 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Hemoglobin A1C (A1C)(Percentage A1C) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Mean | 8.17 ± 0.90 | 8.06 ± 0.89 | 8.13 ± 0.93 | 8.12 ± 0.90 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Mean | 169.1 ± 41.7 | 168.1 ± 45.5 | 167.5 ± 44.4 | 168.3 ± 43.8 |
| Body Weight(Kilograms) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Mean | 84.5 ± 17.1 | 84.8 ± 17.2 | 85.3 ± 16.5 | 84.9 ± 16.9 |
| Sitting Systolic Blood Pressure (SBP)(mmHg) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Mean | 129.30 ± 15.43 | 130.48 ± 13.77 | 130.37 ± 12.00 | 130.05 ± 13.80 |
| Diastolic Blood Pressure (DBP)(mmHg) | Placebo/Glimepiride | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Total |
|---|---|---|---|---|
| Mean | 77.45 ± 7.55 | 78.45 ± 8.32 | 78.08 ± 7.45 | 77.99 ± 7.78 |
9 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2013 to primary completion in Aug 2017, 43 months.
Results were first posted in Sep 2018, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 43 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin